» Articles » PMID: 16037401

Chronic Intermittent Hypoxia Upregulates Genes of Lipid Biosynthesis in Obese Mice

Overview
Date 2005 Jul 23
PMID 16037401
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

Obstructive sleep apnea (OSA), a condition tightly linked to obesity, leads to chronic intermittent hypoxia (CIH) during sleep. There is emerging evidence that OSA is independently associated with insulin resistance and fatty liver disease, suggesting that OSA may affect hepatic lipid metabolism. To test this hypothesis, leptin-deficient obese (ob/ob) mice were exposed to CIH during the light phase (9 AM-9 PM) for 12 wk. Liver lipid content and gene expression profile in the liver (Affymetrix 430 GeneChip with real-time PCR validation) were determined on completion of the exposure. CIH caused a 30% increase in triglyceride and phospholipid liver content (P < 0.05), whereas liver cholesterol content was unchanged. Gene expression analysis showed that CIH upregulated multiple genes controlling 1) cholesterol and fatty acid biosynthesis [malic enzyme and acetyl coenzyme A (CoA) synthetase], 2) predominantly fatty acid biosynthesis (acetyl-CoA carboxylase and stearoyl-CoA desaturases 1 and 2), and 3) triglyceride and phospholipid biosynthesis (mitochondrial glycerol-3-phosphate acyltransferase). A majority of overexpressed genes were transcriptionally regulated by sterol regulatory element-binding protein (SREBP) 1, a master regulator of lipogenesis. A 2.8-fold increase in SREBP-1 gene expression in CIH was confirmed by real-time PCR (P = 0.001). Expression of major genes of cholesterol biosynthesis, SREBP-2 and 3-hydroxy-3-methylglutaryl-CoA reductase, was unchanged. In conclusion, we have shown that CIH may exacerbate preexisting fatty liver of obesity via upregulation of the pathways of lipid biosynthesis in the liver.

Citing Articles

Association of Obstructive Sleep Apnea with Nonalcoholic Fatty Liver Disease: Evidence, Mechanism, and Treatment.

Wang L, Liu H, Zhou L, Zheng P, Li H, Zhang H Nat Sci Sleep. 2024; 16:917-933.

PMID: 39006248 PMC: 11244635. DOI: 10.2147/NSS.S468420.


Association between hemoglobin and non-alcoholic fatty liver disease (NAFLD) in United States adults: Results from NHANES 2017-2020.

Yao K, Chen Z, Zhou W, Liu Z, Cui W Prev Med Rep. 2024; 44:102798.

PMID: 38983448 PMC: 11231751. DOI: 10.1016/j.pmedr.2024.102798.


Assessing causality between obstructive sleep apnea with the dyslipidemia and osteoporosis: a Mendelian randomization study.

Hong P, Liu D, Liu A, Su X, Zhang X, Zeng Y Front Genet. 2024; 15:1359108.

PMID: 38966010 PMC: 11222592. DOI: 10.3389/fgene.2024.1359108.


Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease.

Gu C, Bernstein N, Mittal N, Kurnool S, Schwartz H, Loomba R J Clin Med. 2024; 13(8).

PMID: 38673503 PMC: 11050527. DOI: 10.3390/jcm13082231.


T266M variants of ANGPTL4 improve lipid metabolism by modifying their binding affinity to acetyl-CoA carboxylase in obstructive sleep apnea.

Li X, Li C, Xue W, Wei Z, Shen H, Wu K Ann Med. 2024; 56(1):2337740.

PMID: 38574398 PMC: 10997356. DOI: 10.1080/07853890.2024.2337740.